LGR5 and neoplasm: Studies in patient-derived organoid and xenograft models showed that petosemtamab more effectively inhibited tumor growth and metastasis than cetuximab, highlighting its unique capacity to exploit LGR5 upregulation as a therapeutic vulnerability [100].